Sugi Predict

Sugi Predict / Targets / HSD17B11

HSD17B11

Estradiol 17-beta-dehydrogenase 11 · Q8NBQ5 · HSD17B11 on Sugi Atlas →

0 patent compounds predicted against HSD17B11, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to HSD17B11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS) PHASE3COMPLETED
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study PHASE3UNKNOWN
AMG 386 and Abiraterone for Advanced Prostate Cancer PHASE2COMPLETED
Androgen Reduction in Congenital Adrenal Hyperplasia PHASE2WITHDRAWN
Letrozole for Lymphangioleiomyomatosis PHASE2COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer PHASE1/PHASE2RECRUITING
Metyrapone as Additive Treatment in Major Depression PHASE2COMPLETED
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency PHASE1COMPLETED
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy PHASE1COMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency nanUNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers nanUNKNOWN
Linear Growth of Children With Congenital Adrenal Hyperplasia nanUNKNOWN
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes nanNOT_YET_RECRUITING
Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS) nanCOMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency nanCOMPLETED
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment nanUNKNOWN
Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome nanUNKNOWN
Furocyst - Poly Cystic Ovary Syndrome Study nanCOMPLETED
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas nanUNKNOWN
Meal Timing on Glucose and Hyperandrogenism in PCOS Women nanUNKNOWN
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome nanCOMPLETED
Final Height in Patients With CAH nanUNKNOWN
Aromatase Inhibitor Clinical Trial nanUNKNOWN
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Cortisol Regulation in Polycystic Ovary Syndrome (PCOS) nanCOMPLETED
Evaluation of Endocrine and Metabolic Parameters in the New Diagnostic Phenotypes of Polycystic Ovary Syndrome nanUNKNOWN
Impact of 11-oxygenated Androgens on Metabolic Dysfunction of Women With Polycystic Ovary Syndrome nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a HSD17B11 binder may also engage these)

ProteinNameSimilarity
Q4JK73 — 1.000 Q4JK73 →
Q5NVG2 — 1.000 Q5NVG2 →
HSD17B13 17-beta-hydroxysteroid dehydrogenase 13 1.000 landscape →
Q9EQ06 — 1.000 Q9EQ06 →
Q8N3Y7 — 1.000 Q8N3Y7 →
Q5M875 — 0.999 Q5M875 →
Q6AYS8 — 0.998 Q6AYS8 →
Q05A13 — 0.995 Q05A13 →
Q8VCR2 — 0.995 Q8VCR2 →
A5PJJ7 — 0.994 A5PJJ7 →
Q7T2D1 — 0.994 Q7T2D1 →
Q9STY7 — 0.993 Q9STY7 →
Q80ZF7 — 0.991 Q80ZF7 →
P0DKC6 — 0.991 P0DKC6 →
P0DKC5 — 0.991 P0DKC5 →
Q8HZT6 — 0.990 Q8HZT6 →
Q8IZV5 — 0.990 Q8IZV5 →
Q8VCH7 — 0.990 Q8VCH7 →
Q7TQA3 — 0.990 Q7TQA3 →
Q5XGF7 — 0.989 Q5XGF7 →
O17795 — 0.989 O17795 →
A1L1W4 — 0.989 A1L1W4 →
Q6DCT3 — 0.988 Q6DCT3 →
P70385 — 0.988 P70385 →
Q17704 — 0.988 Q17704 →
Q6NRV4 — 0.987 Q6NRV4 →
Q9STY8 — 0.987 Q9STY8 →
Q5ZJG8 — 0.987 Q5ZJG8 →
O70503 — 0.987 O70503 →
A5PJF6 — 0.987 A5PJF6 →